Review article: Proton pump inhibitors with clopidogrel - Evidence for and against a clinically-important interaction

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 7, 2011, Pages 758-767

  Disney, B R ^a   Watson, R D S ^a   Blann, A D ^b   Lip, G Y H ^b   Anderson, M R ^a  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE CORONARY SYNDROME; ANTIPLATELET ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INTESTINE ABSORPTION; KIDNEY FAILURE; MONOTHERAPY; MORNING DOSAGE; MORTALITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STENT THROMBOSIS; STROKE; THERAPY EFFECT; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ASPIRIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK; TICLOPIDINE;

EID: 79952259717     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04585.x     Document Type: Review

References (73)

1. Yusuf S, Zhoa F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
2. Ng F, Wong S, Lam K, et al. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastro 2008; 103: 865-71. (Pubitemid 351501090)
3. Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. J Am Coll Cardiol 2009; 54: 1293-302.
4. Laine L,. Review article: gastrointestinal bleeding with low-dose aspirin-what's the risk? Aliment Pharmacol Ther 2006; 24: 897-908. (Pubitemid 44326371)
5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
6. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
7. Gilard M, Arnaud B, Comily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
8. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J,. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thrombo Haemost 2006; 4: 2508-9. (Pubitemid 44575451)
9. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
10. European Medicines Agency. Public Statement on Possible Interaction Between Clopidogrel and Proton-Pump Inhibitors. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf. Accessed January 25, 2010.
11. Food and Drug Administration. Information for Healthcare Professionals: Update to the Labelling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Healthcare Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafety-InformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed January 25, 2010.
12. Moayyedi P, Sadowski DC,. Proton Pump inhibitors and clopidogrel- hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol 2009; 23: 251-2.
13. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-7. (Pubitemid 44497506)
14. Richter T, Mürdter TE, Heinkele G, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004; 308: 189-97. (Pubitemid 38090717)
15. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite ex vivo. J Am Coll Cardiol 2008; 52: 1968-77.
16. De Miguel A, Ibanez B, Badimõn JJ,. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
17. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
18. Kurihara A, Hagihara K, Kazui M, Ishizuka T, Farid NA, Ikeda T,. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev 2005; 37 (Suppl. 2): 99.
19. Rehmal JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-7.
20. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-7. (Pubitemid 24251300)
21. Siller-Matula J, Schror K, Wojta J, Huber K,. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-93. (Pubitemid 46437800)
22. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV,. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-31. (Pubitemid 47069129)
23. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16. (Pubitemid 46517957)
24. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
25. Fontana P, Hulot JS, De Moerloose P, Gaussem P,. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007; 5: 2153-5. (Pubitemid 47450038)
26. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
27. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
28. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17.
29. Desta Z, Zhao X, Shin JG, Flockhart DA,. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58. (Pubitemid 35168437)
30. Goldstein JA,. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55. (Pubitemid 32939439)
31. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-22.
32. Neubauer H, Mugge A,. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Des 2006; 12: 1271-80. (Pubitemid 44082136)
33. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7. (Pubitemid 36070929)
34. Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008; 28: 1483-94.
35. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-4. (Pubitemid 37048218)
36. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-8. (Pubitemid 36897711)
37. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50: 291-5. (Pubitemid 47058889)
38. Ishizaki T, Horai Y,. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl. 3): 27-36. (Pubitemid 29389409)
39. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-84. (Pubitemid 351389118)
40. Li XQ, Andersson TB, Ahlstrom M, Weidolf L,. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-7. (Pubitemid 38955611)
41. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-9.
42. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
43. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B,. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 145-8.
44. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54: 1149-53.
45. Norgard NB, Mathews KD, Wall GC,. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009; 43: 1266-74.
46. Juhasz M, Herszenyi L, Tulassay Z,. Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the Gastroenterologist. Digestion 2010; 81: 10-5.
47. Juurlink DN,. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009; 120: 2310-2.
48. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010; 56: 2051-66.
49. Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (SPICE). Available at: http://clinicaltrials. gov/ct2/show/NCT00930670. Accessed November 30, 2010.
50. Aubert R, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study (abstract 3998). Circulation 2008; 118: S815.
51. Pezalla E, Day D, Pullidath I,. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52: 1038-9.
52. Last EJ, Sheehan AH,. Review of recent evidence: potential interactions between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm 2009; 66: 2117-22.
53. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S,. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-9.
54. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial (abstract 3999). Circulation 2008; 118: S815.
55. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
56. Sibbing D, Kastrati A,. Risk of combining PPIs with thienopyridines: fact or fiction. Lancet 2009; 374: 952-3.
57. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010; 26: e54-7.
58. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-45.
59. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
60. Valkhoff VE, 't Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC,. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011; 33: 77-88.
61. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007; 116: 2793-801. (Pubitemid 350291221)
62. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-66.
63. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 2007; 49: 1362-8. (Pubitemid 46476844)
64. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S,. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82. (Pubitemid 44268228)
65. Rude MK, Chey WD,. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between? Gastroenterology 2009; 137: 1168-71.
66. Giraud MN, Sanduja SK, Felder TB, Illich PA, Dial EJ, Lichtenberger LM,. Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther 1997; 11: 899-906. (Pubitemid 27445676)
67. Lichtenberger LM, Ulloa C, Romero JJ, Vanous AL, Illich PA, Dial EJ,. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology 1996; 111: 990-5. (Pubitemid 26327601)
68. Hollander D, Dadufalza VD, Fairchild A,. Intestinal absorption of aspirin. J Lab Clin Med 1981; 98: 591-8.
69. Iñarrea P, Esteva F, Cornudella R, Lanas A,. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 2000; 35: 242-6. (Pubitemid 30217174)
70. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol 2009; 54: 163-8.
71. Kasprzak M, Koziński M, Bielis L, et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 2009; 16: 535-44.
72. Würtz M, Grove EL, Kristensen SD, Hvas AM,. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010; 96: 368-71.
73. Sung JJ,. Marshall and Warren Lecture 2009: peptic ulcer bleeding: an expedition of 20 years from 1989-2009. J Gastroenterol Hepatol 2010; 25: 229-33.